

The 2nd Symposium on Transporters in Drug Discovery and Development

Features of the Meeting

The conference programme will cover:

- Lectures on transporter structural biology, the impact of transporters on ADME and biodistribution, transporters as therapeutic targets and the toxicological impact of transporter interactions on drug development
- Poster session
- Related trade exhibition
- Conference dinner on Monday evening (included in the registration fee)

Call for Posters

Abstracts for poster presentation are invited, and a template is available on the event website. Closing date for posters is 31st March.

Venue

The Library, Royal Society of Chemistry at Burlington House, Piccadilly, London W1J 0BA. Situated in central London, this venue is easily accessible by public transport.

Registration and Students

Registration is open. Registration fees include attendance at the conference dinner (opt in is required). Discounted rates are offered to members of the RSC, SCI and DMDG, and some students bursaries are available.

	Early (payments received by 8th Feb)	Standard (payments received 9th Feb-12 Apr)
RSC, SCI or DMDG member	£250	£350
Non-member	£330	£465
RSC, SCI or DMDG student* member	£140	£180
Student* non-member	£160	£220

Late payment fee of £30 will be added to the above standard rates for payments received from 13th April onwards

* Student is undergraduate or post-graduate. Student rate does not apply to post-docs or students in paid employment.

Member is paid-up member of the RSC, SCI or DMDG.

Sponsorship and Exhibition Opportunities

There will be a relevant trade exhibition (see website for charges). We are grateful to Evotec for their sponsorship of this meeting, and additional sponsors are encouraged to support this second event.

Secretariat Contact

Maggi Churchouse
3 East Barn, Market Weston Road,
Theltham, Diss IP22 1JJ, UK
Telephone: +44 (0)1359 221004
E-mail: maggi@maggichurousevents.co.uk


Website Address

www.maggichurousevents.co.uk/bmcs
also www.RSC.org/BMCS, www.SOCI.org/events, www.dmdg.org/events



Organising Committee

Sharan Bagal AstraZeneca
Adrian Hall UCB
Sarah Major Evotec
David Miller Inflazome
Graeme Scarfe AstraZeneca
Jason Tierney Discovery from Charles River
Andrew Williams Lilly (chairman)



Second Announcement and Call for Posters

The 2nd Symposium on Transporters in Drug Discovery and Development

Monday-Tuesday, 15th-16th May 2017

Royal Society of Chemistry at Burlington House
London, UK



Organised by the Royal Society of Chemistry's Biological and Medicinal Chemistry Sector, the DMDG, and the Society of Chemical Industry's Fine Chemicals Group

Synopsis and Programme

Synopsis

Cell surface transporters play a key role in human health and disease, both through their impact on drug disposition and as therapeutic targets in their own right. This meeting continues on from the first, successfully held in 2014, and is anticipated to become part of a regular series. It should be of interest to medicinal chemists, DMPK scientists and other workers concerned with the impact of transporters on human health.

Programme

Day 1 Monday, 15th May

12:00 Registration and lunch

13:00 Opening remarks

Session 1 - Therapeutic Targets I

Session chair - Jason Tierney, Discovery from Charles River, UK

13:10 *Solute Carriers (SLCs) as drug targets: challenges and opportunities*
David Hepworth, Pfizer, USA

13:50 *Structural biology of human solute carriers at the SGC*
Liz Carpenter, SGC Oxford, UK

14:20 *Biochemical and biophysical dissection of the molecular events in Na⁺-coupled substrate transport by a membrane protein*
Peter Henderson, University of Leeds, UK

Session chair - Sarah Major, Evotec, UK

14:50 Flash poster presentations

15:10 Refreshments and posters

Session 2 - ADME I

Session chair - Graeme Scarfe, AstraZeneca, UK

15:40 *Predicting the impact of transporters on systemic and tissue pharmacokinetics: a look at the utility of in vitro systems and modelling approaches*
Mohammed Ullah, Roche, Switzerland

16:10 *Transporter-mediated drug-drug interactions Prediction by Physiologically-based Pharmacokinetic Modelling (PBPK): an industry perspective*
Venkatesh Pilla Reddy, AstraZeneca, UK

16:40 *The impact of agency-relevant transporters and permutations of likely interactions with enzymes through clinical studies: an impossible task that can be replaced by in silico clinical trials of drug candidates*
Amin Rostami, University of Manchester, UK

17:20 Drinks reception, exhibition and posters

18:40 Close, walk to conference dinner

19:00 Conference dinner at Gaucho, Piccadilly

Programme

Day 2 Tuesday 16th May

Session 3 - ADME II

Session chair - David Miller, Inflazome, UK

09:00 *Humanized animal models - potential tools for the study of drug transporters?*

Laurent Salphati, Genentech, USA

09:40 *Hepatic uptake and drug disposition - in vitro and in silico approaches*
Sarah Foley, Evotec, UK

10:10 *Role of human influx and efflux transporters in renal clearance of organic anions*

Elnaz Gozalpour, AstraZeneca, UK

10:40 Refreshments and exhibition

Session 4 - Therapeutic Targets II

Session chair - Adrian Hall, UCB, Belgium

11:10 *Pharmacologic characterization of a selective and specific VMAT2 inhibitor: implications for the treatment of tardive dyskinesia*
Grace Liang, Neurocrine, USA

11:50 *Discovery, characterization and optimization of sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitors for the treatment of metabolic diseases*

David Hepworth, Pfizer, USA

12:30 Lunch, exhibition and posters

Session 5 - ADME III

Session chair - Sharan Bagal, AstraZeneca, UK

13:30 *Correction of passive permeation in an in vitro model to predict the extent of Pgp-mediated efflux in brain disposition*
Johan Nicolaï, UCB, Belgium

14:00 *Clinical relevance of intestinal BCRP inhibition in drug-drug interactions (DDIs): a perspective on assessing BCRP-mediated DDI risk liability during drug discovery and development*
Robert Elsby, Cyprotex, UK

14:30 *Importance of endogenous transporter biomarkers in prediction of transporter mediated drug-drug interactions*
Kunal Taskar, GlaxoSmithKline, UK

15:00 Refreshments

Session 6 - Therapeutic Targets III

Session chair - Andrew Williams, Lilly, UK

15:30 *Using PET to study transporter mediated DDIs in tissues*
Oliver Langer, Medical University of Vienna, Austria

16:10 *Use of the folate and other transporters for drug delivery to cancers, inflammatory and autoimmune diseases*
Phil Low, Purdue University, USA

16:50 Closing remarks

17:00 Close